Stocks To Watch: IAC/InterActiveCorp (NASDAQ:IACI), Pharmacyclics (NASDAQ:PCYC), ISIS Pharmaceuticals (NASDAQ:ISIS), Seattle Genetics (NASDAQ:SGEN)

Posted by on Apr 14, 2014

Tinder is not the most respectable of social applications. The location-based messaging application is concentrated on helping users meet new people, though its fame stems from its rumored use in the “casual dating” scene. IAC/InterActiveCorp (NASDAQ:IACI) announced it bought an additional 10% of the company, at a valuation of $5 billion on Friday April 11th. The move forced shares in the company higher. IAC/InterActiveCorp (NASDAQ:IACI), shares after opening at $68.04 moved to $72.34 on last trade day and at the end of the day closed at $68.82. Company price to sales ratio in past twelve months was calculated as 1.87 and price to cash ratio as 5.11. IAC/InterActiveCorp (NASDAQ:IACI), showed a negative weekly performance of 1.67%.

Pharmacyclics, Inc. (NASDAQ:PCYC) submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for its oncology drug, Imbruvica. Pharmacyclics, Inc. (NASDAQ:PCYC), shares fell 7.67% in last trading session and ended the day on $86.11. Pharmacyclics, Inc. (NASDAQ:PCYC), return on equity ratio is recorded as 13.00% and its return on assets is 10.60%. Pharmacyclics, Inc. (NASDAQ:PCYC), yearly performance is 14.16%.

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) declared the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high to sternly high triglycerides on stable doses of fibrates. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), shares moved down 5.78% in last trading session and was closed at $33.90, while trading in range of $ 33.90 – 37.55. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), year to date (YTD) performance is -14.91%.

Seattle Genetics, Inc. (NASDAQ:SGEN) has earned a milestone payment of $6 million from Takeda Pharmaceutical Company Limited following the first commercial sales of Adcetris in key countries (Australia, South Korea and Mexico). Seattle Genetics, Inc. (NASDAQ:SGEN), weekly performance is -7.54%. On last trading day company shares ended up $37.17. Seattle Genetics, Inc. (NASDAQ:SGEN), distance from 50-day simple moving average (SMA50) is 23.26%. Analysts mean target Price for the company is $4.08.

Leave a Reply